Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) continues to be a global threat due to its ability to evolve and generate new subvariants, leading to new waves of infection. Additionally, other coronaviruses like Middle East respiratory syndrome coronavirus (MERS-CoV, formerly know...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Nadine Alvarez, Gregory C. Adam, John A. Howe, Vijeta Sharma, Matthew D. Zimmerman, Enriko Dolgov, Risha Rasheed, Fatima Nizar, Khushboo Sahay, Andrew M. Nelson, Steven Park, Xiaoyan Zhou, Christine Burlein, John F. Fay, Daniel V. Iwamoto, Carolyn M. Bahnck-Teets, Krista L. Getty, Shih Lin Goh, Imad Salhab, Keith Smith, Christopher W. Boyce, Tamara D. Cabalu, Nicholas Murgolo, Nicholas G. Fox, Todd W. Mayhood, Valerie W. Shurtleff, Mark E. Layton, Craig A. Parish, John A. McCauley, David B. Olsen, David S. Perlin
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2024-07-01
Rangatū:	Viruses
Ngā marau:	coronavirus SARS-CoV-2 MERS-CoV 3CLPro antivirals protease inhibitors
Urunga tuihono:	https://www.mdpi.com/1999-4915/16/7/1158
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling

Ngā tūemi rite